Clinical and pharmacological group: & nbsp

Inhibitors of fibrinolysis

Included in the formulation
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    ONLS

    АТХ:

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:

    Analog of lysine. Competing for lysine binding sites in active centers plasminogen and plasmin, blocking the interaction of plasmin with fibrin. Has the ability to competitively inhibit plasminogen activators. In high doses reduces the activity of plasmin. Inhibits biogenic polypeptides - kinins.

    Deactivates streptokinase, urokinase and tissue kinases involved in fibrinolysis. Neutralizes hyaluronidase, kallikrein and trypsin, reduces the permeability of capillaries.

    Pharmacokinetics:Half-life is 2 hours. Elimination of the kidneys unchanged.
    Indications:

    It is used in surgery as a means for local hemostasis in bleeding disorders, including those associated with haemophilia with hemorrhagic syndromes, disorders of internal organs, in complicated abortion. As a prophylactic against secondary hypophybrinogenemia with massive blood transfusion.

    XVIII.R50-R69.R58   Bleeding, not elsewhere classified

    XIX.T80-T88.T81.0   Bleeding and hematoma complicating the procedure, not elsewhere classified

    Contraindications:

    For parenteral administration:

    - DIC-syndrome;

    - coagulopathy, propensity to thrombosis;

    - Pregnancy;

    - Hematuria - increased risk of acute renal failure.

    Local application for surgical interventions is not limited.

    Individual intolerance.

    Carefully:

    In cases of cerebral circulation disorders, the risk of thrombosis.


    Pregnancy and lactation:

    Pregnancy and lactation: recommendations for FDA - С. The drug is contraindicated in lactation.

    Dosing and Administration:

    Use in children

    It is used for acute bleeding inside or intravenous drip of 100 mg / kg for 1 hour, then the dose is reduced to 33.3 mg / kg of weight. The total dose of 18 g / kg, the duration of treatment - no more than 24 hours.

    In dentistry: for prevention of bleeding in hemophilia - rinsing. 5 ml is kept in the mouth for 30 seconds. You can rinse 4 times a day for 7-10 days. Admissible minor ingestion of the drug.

    With diapedesis bleeding during surgery, topically, in the form of tampons or napkins, which are applied over the entire area of ​​the wound surface in 1-2 layers before resorption of the drug.

    When cardiac surgery: 5 g intravenously to connect the device of artificial circulation, or 10 g after giving anesthesia before the cut of the skin, 10 g after the administration of heparin and the same (10 g) after the introduction of protamine.

    Subarachnoid hemorrhage: intravenously 6-9 g / day with the purpose of preventing recurrent bleeding. The measure is effective in the first day of the disease.

    When transfused canned blood: intravenously drip (or with a dispenser) 4-5 g for one hour, then 1 g in 50 ml of saline every hour for 8 hours or until the bleeding stops.

    Prophylaxis and treatment of bleeding in dental practice: inside 75 mg / kg (not more than 6 g) or in the same dose intravenously drip immediately after the intervention, then every 6 hours for 10 days.

    The highest daily intake for adults: 30 g, for children - 18 g.

    The highest single dose: 10 g and 5 g, respectively.

    Side effects:

    Cardiovascular system: hypotension, bradycardia.

    Gastrointestinal tract: spasms in the abdomen.

    Skin: rash.

    Allergic reactions.

    Overdose:

    The cardiovascular system: collapse, thromboembolism.

    Central nervous system: delirium.

    Gastrointestinal tract: necrosis of the liver.

    Treatment: withdrawal of the drug, symptomatic therapy.

    Interaction:

    Thrombolytic enzyme antagonist.

    To avoid thromboembolic complications, administration of aminocaproic acid is possible only after 8 hours after the patient has received any coagulation factors.

    The combination of hormonal contraceptives with aminocaproic acid also helps to increase thrombogenesis.

    Special instructions:

    Monitoring of creatinine in long-term treatment. The increase in CK is the basis for the withdrawal of the drug.

    Some dosage forms of aminocaproic acid contain 0.9% benzyl alcohol (preservative), which can contribute to asphyxia of newborns, intracranial hemorrhage, collapse.

    Instructions
    Up